Graffinity and Amgen enter into drug discovery research agreement
28 Feb 2007 -
Graffinity Pharmaceuticals GmbH announced that it has entered into a research collaboration with Amgen. Under the terms of the agreement, Graffinity will receive technology access fees and success payments for the generation of novel small molecule hits against a broad range of drug targets. Amgen will gain access to Graffinity's proprietary fragment-based drug discovery technology which uses chemical
microarrays to screen for small molecule fragments that bind to a variety of drug targets which play a key role in major human diseases. The identification of novel modes of action and chemistry is a major focus of the collaboration. Financial details of the transaction were not disclosed.
Additional information
Amgen Inc. Thousand Oaks, CA, United States of America
Top
Contact
Print version
Send article
RSS feed